Mary Feng, MD
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma (NCT04430452) | Mary Feng, MD | 2022-02-04 |
Track Mary Feng, MD automatically
Every clearance here is in the API, with alerts when new ones post.